Zobrazeno 1 - 10
of 32
pro vyhledávání: '"J.O. Buchanan"'
Autor:
Marianne E. Federici, Nicholas A. Meanwell, C.L. Brassard, George B. Zavoico, J.O. Buchanan, Steven M. Seiler, J. Stuart Fleming
Publikováno v:
Thrombosis Research. 74:115-123
BMY 42393, (2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid), is a new prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation (IC 50 range 0.3 - 2.0 μM). BMY 42393 stimulated platelet adenylate
Autor:
Michael J. Rosenfeld, J.O. Buchanan, C.L. Brassard, Wright John J, Jeffrey L. Romine, Scott W. Martin, M F Malley, Nicholas A. Meanwell, J Z Gougoutas, Ashok K. Trehan
Publikováno v:
Journal of Medicinal Chemistry. 36:3884-3903
cis-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethenyl]phenoxy]acetic acid (3) was previously identified as a nonprostanoid prostacyclin (PGI2) mimetic that potently inhibits ADP-induced aggregation of human platelets with an IC50 of 0.18 microM. As part of an e
Autor:
Marianne E. Federici, Karen S. Hartl, M. J. Rosenfeld, Nicholas A. Meanwell, S. M. Seiler, M. Gamberdella, C.L. Brassard, George B. Zavoico, Wright John J, J.O. Buchanan, J. S. Fleming
Publikováno v:
ChemInform. 25
Autor:
Wright John J, H. R. Roth, Dennis Rd, Michael J. Rosenfeld, E. Gillespie, J.O. Buchanan, C.L. Brassard, Nicholas A. Meanwell, M. Gamberdella, E. C. R. Smith
Publikováno v:
Journal of Medicinal Chemistry. 35:2688-2696
Two series of 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives incorporating an additional site for acid salt formation were synthesized and evaluated as inhibitors of human blood platelet cAMP phosphodiesterase (PDE) and ADP-induced platelet
Autor:
Nicholas A. Meanwell, Michael J. Rosenfeld, J. Stuart Fleming, Marianne E. Federici, J.O. Buchanan, J. J. Kim Wright, C.L. Brassard, Steven M. Seiler
Publikováno v:
Journal of Medicinal Chemistry. 35:389-397
A series of phenylated pyrazoloalkanoic acid derivatives were synthesized and evaluated as inhibitors of ADP-induced human platelet aggregation. 3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (8d), with an IC50 of 0.4 microM, was the most potent inhibit
Publikováno v:
Thrombosis Research. 63:145-155
BMY-43351 is a new broad-spectrum inhibitor of platelet aggregation with greater aqueous solubility than earlier analogs from the imidazoquinoline series. This report compares the antithrombotic activity of BMY-43351 to that of two other imidazoquino
Autor:
J.O. Buchanan, William A. Schumacher, J. Stuart Fleming, M. Gamberdella, Steven M. Seiler, George B. Zavoico, Nicholas A. Meanwell
Publikováno v:
Thrombosis research. 74(2)
The oral activity and antithrombotic efficacy of BMY 42393 was examined in ex vivo platelet aggregation studies and arterial thrombosis animal models. In a heterologous ex vivo platelet aggregation assay, ADP-induced human platelet aggregation was in
Autor:
Marianne E. Federici, C.L. Brassard, Michael J. Rosenfeld, Karen S. Hartl, Nicholas A. Meanwell, M. Gamberdella, J.O. Buchanan, George B. Zavoico, J. S. Fleming, Wright John J
Publikováno v:
Journal of medicinal chemistry. 36(24)
The 4,5-diphenyloxazole derivatives 2-4 were previously identified as nonprostanoid prostacyclin (PGI2) mimetics. A series of derivatives of 2-4 bearing substitutents at the carbon atom alpha to the oxazole ring were synthesized and evaluated as inhi
Autor:
J. Stuart Fleming, Jeffrey L. Romine, J.O. Buchanan, George B. Zavoico, Ashok K. Trehan, Steven M. Seiler, Michael J. Rosenfeld, C.L. Brassard, Marianne E. Federici, J. J. Kim Wright, Nicholas A. Meanwell, M. Gamberdella
Publikováno v:
Journal of medicinal chemistry. 35(19)
4,5-Diphenyl-2-oxazolenonanoic acid (2) and 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid (3) were previously identified as nonprostanoid prostacyclin (PGI2) mimetics that inhibit ADP-induced aggregation of human platelets in vitro. The
Autor:
E. Gillespie, D. L. Wedding, E. C. R. Smith, M. Gamberdella, Nicholas A. Meanwell, Bradley C. Pearce, J.O. Buchanan, U.M. Baryla, H. R. Roth, Wright John J
Publikováno v:
Journal of medicinal chemistry. 35(14)
A series of 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives, substituted at the 7-position with functionalized side chains, was synthesized and evaluated as inhibitors of human blood platelet cAMP phosphodiesterase (PDE) as well as ADP- and c